Microbix Biosystems Valuation
Is MBX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MBX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MBX (CA$0.3) is trading above our estimate of fair value (CA$0)
Significantly Below Fair Value: MBX is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MBX?
Key metric: As MBX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is MBX's PE Ratio? | |
|---|---|
| PE Ratio | 8x |
| Earnings | CA$5.08m |
| Market Cap | CA$42.03m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 11.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does MBX's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 29.9x | ||
IBT IBEX Technologies | 8.9x | n/a | CA$35.3m |
MDP Medexus Pharmaceuticals | 16.4x | 49.9% | CA$53.0m |
HASH Simply Solventless Concentrates | 55.2x | n/a | CA$53.2m |
WOLF Grey Wolf Animal Health | 39.3x | n/a | CA$27.3m |
MBX Microbix Biosystems | 8x | n/a | CA$42.0m |
Price-To-Earnings vs Peers: MBX is good value based on its Price-To-Earnings Ratio (8x) compared to the peer average (29.9x).
Price to Earnings Ratio vs Industry
How does MBX's PE Ratio compare vs other companies in the North American Biotechs Industry?
| 12 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: MBX is good value based on its Price-To-Earnings Ratio (8x) compared to the North American Biotechs industry average (15.8x).
Price to Earnings Ratio vs Fair Ratio
What is MBX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MBX's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fennec Pharmaceuticals
US$127.3m
Operates as a biopharmaceutical company in the United States.
FRX
US$6.59
7D
8.0%
1Y
-43.4%
Verano Holdings
CA$829.5m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$2.14
7D
-15.4%
1Y
-63.8%
Medexus Pharmaceuticals
CA$53.0m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.13
7D
4.9%
1Y
38.3%